A Japanese phase 2 clinical study of netarsudil ophthalmic solution showed a significant reduction in mean intraocular pressure compared with placebo, Aerie Pharmaceuticals announced in a press release.
The 28-day study evaluated the safety and efficacy of three netarsudil concentrations of 0.01%, 0.02% and 0.04% in 215 subjects with open-angle glaucoma or ocular hypertension. Two hundred and seven subjects completed the study.
A mean diurnal IOP reduction between 4.1 mm Hg and 4.6 mm Hg was recorded in patients treated with the 0.01% concentration. In the 0.02% concentration arm, mean diurnal